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SUMMARY
Inhibitors of cyclic nucleotide phosphodiesterases are known to suppress lipopolysaccharide
(LPS)-induced tumour necrosis factor-alpha (TNF-a) production in vitro in human monocytes.
The most potent of these have selectivity for type IV PDEs, suggesting that this class of PDE is the
major type involved in the regulation of human TNF-a production. Using compounds of two
distinct chemical structural classes, a quinazolinedione (CP-77 059) and a 4 arylpyrrolidinone
(rolipram), we show here that PDE-IV-specific inhibitors are also potent in suppressing LPS-
induced TNF-a production in vitro in sodium periodate-elicited murine macrophages (IC50s of 1
and 33, respectively). We then report the in vivo anti-inflammatory effect of PDE-IV inhibition in
five murine models of inflammation: (i) elevation of serum TNF-a induced by a sublethal LPS
injection; (ii) LPS-induced endotoxic shock; (iii) LPS/galactosamine-induced endotoxic shock; (iv)
carrageenan-induced paw oedema; and (v) adjuvant arthritis. Following a sublethal (5 Mg/mouse)
injection of LPS, serum TNF-a levels in mice peaked sharply, reaching concentrations of 3-12 ng/
ml 90 min after injection. In this sublethal LPS assay, CP-77 059 was about 30 times more potent
than rolipram, with a minimum effective dose of 0-1 mg/kg versus 3mg/kg for rolipram. This rank
order is in keeping with the relative in vitro IC50s for CP-77 059 and rolipram, as well as their
relative Ki against the human PDE-IV enzyme (46 nm and 220 nM, respectively). In LPS-induced
endotoxic shock, rolipram and CP-77 059 at relatively high doses of 30 and 10 mg/kg, respectively,
significantly reduced serum TNF-a levels, and also inhibited mortality 66%. In the LPS/
galactosamine shock model, in which mice are rendered exquisitely sensitive to LPS by co-
injection with galactosamine, only 0l ,ug of LPS/mouse is necessary for serum TNF-a elevation
and death. Both rolipram and the CP-77 059 caused dose-dependent reduction of serum TNF-a
and lethality. In the carrageenan-induced paw oedema model, in which there is a pronounced local
TNF-a response (without a serum TNF-a elevation), rolipram significantly inhibited paw swelling
as well as localized TNF-a levels in the paw. In the adjuvant arthritis model, a chronic model of
inflammation also possessing localized TNF-a elevation in the inflamed paw, rolipram and CP-
77059 suppressed ankle swelling and radiological evidence of joint damage. These data are
consistent with a major role for PDE-IV in regulation of TNF-a production and inflammatory
responses in murine systems. It suggests a potential therapeutic use for PDE-IV-specific inhibitors
in inflammatory disease such as rheumatoid arthritis, septic shock and other inflammatory diseases
where TNF-a has been postulated to be a contributing factor in the pathology of the disease.
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INTRODUCTION major role in the response of inflammatory cells to a wide range
The intracellular concentration of cAMP appears to play a of stimuli [1-4]. This is supported primarily by the similareffects on cell function of a variety of cyclic nucleotide-elevating
Correspondence: Dr Les Sekut, Glaxo Research Institute, 5 Moore agents including cAMP analogues such as dbcAMP, agents
Drive, Research Triangle Park, NC 27709, USA. which stimulate adenylate cyclase activity such as prosta-
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glandin El (PGEI), forskolin and fl2-agonists, and cyclic
nucleotide phosphodiesterase inhibitors which slow the cata-
bolism ofcAMP and cGMP. One of the most striking examples
is the suppressive effect of these agents on the production of
tumour necrosis factor-alpha (TNF-a) monocytes and macro-
phages [5-10].
The relatively recent characterization of several PDE iso-
forms exhibiting differential regulation and tissue expression,
and the availability of inhibitors selective for some of these
isoforms, has spurred efforts to develop further PDE isoform-
selective inhibitors as tools for investigating PDE function and
as potential therapeutics. Based on the effect of prototypic
PDE-IV selective inhibitors such as rolipram, and molecular
cloning efforts, PDE-IV is thought to be a major phosphodies-
terase isoform responsible for catabolism ofcAMP and regula-
tion of inflammatory function in many cells, including
monocytes, lymphocytes, mast cells, basophils and neutrophils
[1-4,11].
Like IL-1,3, TNF-a is a pluripotent cytokine believed to be
involved in the pathology of a variety of inflammatory diseases
[12-14]. TNF-a bears many of the activities of IL-1, such as
induction of bone resorption, activation of collagenase, stimu-
lation ofprostaglandin release and up-regulation of endothelial
cells [14]. Again like IL-1p, TNF-a appears to play a key role in
septic shock models, as demonstrated by Pfeffer etal. [15].
Presence of localized and systemic TNF-a in acute and chronic
animal models of inflammation has been shown by Sekut et al.
[16] and Smith-Oliver etal. [17].
In the present study, we investigate the effect of PDE-IV-
selective inhibitors, representing two distinct chemical struc-
tural classes, on in vitro and in vivo murine TNF-a production,




Female inbred C57BI/6, C3H/hen and C3H/HeJ mice
(approximately 22 g each) were obtained from Charles River
Laboratories Inc. (Raleigh, NC). Rats used in the carrageenan
oedema studies were 250-g male, Lewis rats purchased from
Charles River Labs. In the adjuvant arthritis model, male Lewis
rats 160-170 g from Charles River Labs were free of patho-
genic viruses as determined by a standard viral titre screen
(Microbiological Associates, Bethesda, MD).
PDE inhibitors
The following PDE inhibitors have been previously described
and were synthesized in house for these studies: PDE-IV-
specific inhibitors rolipram and CP-77 059 [18]; PDE-III-
specific inhibitor CI-930; PDE-V inhibitor zaprinast (Verghese
et al., J Pharm Exp Ther, accepted for publication, 1995).
TNF-cr production by murine macrophages
C3H/HeJ female mice were injected intraperitoneally with 2 ml
of 5 mm NaIO4. Five days later, mice were euthanized and
peritoneal exudate cells collected into cold PBS. Erythrocytes
were lysed with ammonium chloride if necessary. Cells were
plated at 5 x 105 cells/well in a 24-well tissue culture plate and
allowed to adhere for 1 5 h. Non-adherent cells were removed
and test PDE inhibitors were added in RPMI medium with 1%
fetal bovine serum (FBS). Lipopolysaccharide (LPS; Escher-
ichia coli serotype 011 :B4; Sigma Chemical Co., St Louis, MO;
2 5 ng/ml final concentration) was then added and cultures were
incubated for 24 h at 37°C. TNF-a protein was quantified in
the supernatant fluids by a commercial murine TNF-a ELISA
kit (Genzyme Diagnostics, Cambridge, MA).
Sublethal LPS injection
C3H/hen mice received an i.p. injection of 5 ,g LPS in 0-5 ml
PBS. Mice were bled from the abdominal vein 90 min following
i.p. injection (n = 4). The blood was allowed to clot overnight
at 4°C and then centrifuged for 15 min. Serum TNF-a levels
were measured by ELISA kit.
The PDE-IV inhibitors were suspended in a 0-1% methyl
cellulose solution and ground in a homogenizer (Eberbach) to
ensure a uniform suspension. A 0 5-ml volume of compound
was administered to each mouse by oral gavage 30 min before
i.p. injection of LPS. Mice were fasted overnight before dosing.
Endotoxic shock models
Both endotoxic shock models were very similar. They differ
mainly in the amount of LPS used and the additional inclusion
of galactosamine. In the shock model with LPS alone, 500 Htg/
mouse of LPS were injected intraperitoneally into C3H/hen
mice. In the LPS/galactosamine model of shock, C57/BI mice
received an i.p. injection of 0 5 ml of a mixture of LPS (0 -1 pg/
mouse) and galactosamine (600 mg/kg; Aldrich Chemical Co.,
Milwaukee, WI) as previously described [16]. Compounds were
administered and serum was obtained and analysed as in the
sublethal model (n = 4). The survival rate was assessed over a
24-h period (n = 6).
Carrageenan-inducedpaw oedema in rats
A 01l-ml volume of a 1% solution of carrageenan was injected
into the rat hind paw. Animals, previously fasted overnight,
were dosed orally with compound in 0-1% methyl cellulose 1 h
before carrageenan injection. Three hours after injection,
animals were euthanized and paw swelling was measured with
calipers. Each group contained eight animals.
For measurement of local TNF-a, paws were removed,
weighed, snap-frozen in liquid N2, pulverized and homogenized
for 2 min in IOml saline at 4°C as previously described [16]. The
suspension was centrifuged in a microcentrifuge to remove
debris, and the supernatant assayed using the TNF-a ELISA
kit.
Adjuvant arthritis in rats
Rats were injected subcutaneously in the base of the tail with
0 05 ml of Freund's complete adjuvant (FCA) containing
300 pg of Mycobacterium tuberculosis (Difco Labs, Detroit,
MI) as described previously [19]. Compounds were suspended
in a 0-1% solution of methyl cellulose, ground in a homo-
genizer, and administered by oral gavage once daily in a volume
of 2 ml. Ankle diameter was measured throughout the time-
course using calipers. At the end of the experiment, rats were
euthanized, paws were removed and radiological analysis was
performed as previously described [20]. Ankles were scored in a
blinded fashion, and each of the five parameters were evaluated
on a scale of 0-4. The features given a radiological score were
(i) bone demineralization, (ii) bone erosion, (iii) periostitis, (iv)
cartilage space reduction, and (v) soft tissue swelling. Thus the
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Table 1. In vitro effect of phosphodiesterase inhibitors on lipopolysac-
charide (LPS)-induced tumour necrosis factor (TNF) production in
murine peritoneal macrophages
Per cent inhibition*
Concentration (tM) CP-77 059 Rolipram C1930 Zaprinast
0001 55 9 5 0
0 01 67 39 1 1 8
0.1 77 63 28 5
1 82 77 20 7
10 85 81 49 25
*Represents the mean of at least two experiments.
maximum total score could be 20 [20]. Each group contained
eight animals.
Statistical analysis
Comparison of mean serum TNF inhibition and paw swelling
was tested between groups using analysis of variance followed
by Dunnett's test for multiple comparisons. Lethality rates
were compared using Fisher's exact test. Group comparisons
where multiple measurements were made on each animal were
tested using a multivariate analysis of variance with repeated
measures model. Alpha levels for all tests were set at 5%.
RESULTS
TNF-a production by murine macrophages in vitro
The PDE-IV selective inhibitors rolipram and CP-77 059 were
potent suppressors of LPS-induced TNF-a production in Na
periodate-elicited mouse peritoneal macrophages, with IC5os of
approximately 33 nm and 1 nm, respectively (Table 1). This
rank order of potency is the same when the respective Ki
against the human PDE-IV enzyme are calculated; with roli-
pram possessing a Ki of 220 nm (n = 9) and CP-77 059 exhibit-
ing a Ki of 46 nm (n = 4; Feldman et al., accepted for
publication, J Med Chem, 1995).
By contrast, the PDE-III-selective inhibitor C1930 [21] was
weakly active (approximately 1OpM), and zaprinast, a PDE-V
inhibitor [22,23] had little or no effect ( > 10 ,tM).
Sublethal injection ofLPS
As an extension of studies of TNF-a inhibition in vitro, PDE-
IV inhibitors were tested in vivo. Mice were injected intraper-




Fig. 1. Structure of the PDE-IV inhibitors, rolipram and CP-77 059.
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Fig. 2. The effect of PDE-IV inhibitors on serum tumour necrosis
factor-alpha (TNF-a) levels in mice injected with a sublethal concen-
tration of lipopolysaccharide (LPS). Fasted female C3H/hen mice were
injected intraperitoneally with 5 jg LPS. Rolipram (a) or CP-77 059 (b)
was given orally 30 min before LPS injection (n = 4). Blood was taken
from the heart 90 min after LPS injection and serum TNF-ac levels
measured using a commercial available ELISA kit. *Significantly
different (P < 0-05) from LPS control using Dunnett's multiple com-
parison. E,O, Test 1; [1,0, test 2.
TNF-a levels but not to cause death. Rolipram and CP-77 059
(Fig. 1) were given orally 30 min before LPS injection. In two
experiments, rolipram was administered at doses ranging from
I to 30 mg/kg (Fig. 2a). Rolipram had a minimum effective dose
of 3 mg/kg, with maximum inhibition of 92% at 30 mg/kg and
no effect at 1 mg/kg. Similar testing of CP-77 059 resulted in a
minimum effective dose of 0-1 mg/kg (Fig. 2b). Thus CP-77 059
was about 30-fold more potent than rolipram. Background
levels of serum TNF-ca in normal mice were undetectable
(< 50 pg/ml), while serum TNF-a levels in the LPS-injected
mice ranged from 3 to 12 ng/ml.
LPS and LPS/galactosamine-induced endotoxic shock
Since PDE-IV inhibitors were active in their inhibition of
low-dose LPS-induced serum TNF-a elevation, these same
inhibitors were tested in models of endotoxic shock, thought
to depend upon the presence of TNF-a. In the high-dose LPS
shock model, serum TNF-ca levels were evaluated over time and
the 24-h mortality rate recorded (Fig. 3). Just as in the sublethal
model, serum TNF-a levels peaked at 90 min post-injection. At
high doses (10-30mg/kg), CP-77059 and rolipram reduced
mortality rate 66% and serum TNF-a level 81-87%.
In the galactosamine (600 mg/kg) + LPS (0- 1 jg/ml) model
of endotoxic shock, galactosamine destroyed liver function so
that normally non-lethal doses of LPS now caused death. In a
dose response experiment, rolipram (1, 10 and 30mg/kg) and
CP-77 059 (1, 3 and 10mg/kg) inhibited serum TNF-a between
84% and 94% (Fig. 4). Rolipram at the highest dose signifi-
cantly inhibited mortality rate by 66%, while CP-77059 at
doses of 3 and 10mg/kg also significantly inhibited mortality by
50-66%. However, both drugs failed to significantly block
mortality at the lower doses.
Carrageenan oedema
Since elevated TNF-a levels have been observed in extracts of
rat and mouse paws injected with carrageenan [16], rolipram
was tested for anti-inflammatory activity in this model. At a
dose of 3, 10 or 30mg/kg, rolipram significantly inhibited
carrageenan paw oedema by 21%, 43% and 45%, respectively
(Fig. 5). It also significantly inhibited TNF-a levels in homo-
genates from the carrageenan-injected paws, with approxi-
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Fig. 3. Effect of PDE-IV inhibitors on serum tumour necrosis factor-
alpha (TNF-a) levels and the lethality associated with the lipopolysac-
charide (LPS) model of endotoxic shock. Fasted female C3H/hen mice
were injected intraperitoneally with 500 pg LPS (n = 22). Four animals
were bled at each time point. Six animals were observed for 24 h to
establish mortality rate. For further details see Fig. 2 or Materials and
Methods. *Significantly different (P < 0 05) from LPS control using
Dunnett's multiple comparison. A, LPS control; *, rolipram 30 mg,
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Fig.4. Effect of PDE-IV inhibitors on serum tumour necrosis factor-
alpha (TNF-a) levels and the lethality associated with the lipopolysac-
charide (LPS), galactosamine model of endotoxic shock. Fasted female
C57/Bl mice were injected intraperitoneally with 01ljig LPS and
600mg/ kg galactosamine (n= 10). Four animals were bled 90 min
after LPS injection. Six animals were observed for 24 h to establish
mortality rate. For further details see Fig. 2 or Materials and Methods.
*Significantly different (P < 0-05) from LPS control using Dunnett's
multiple comparison. A, CP-77 059 inhibition of lethality; A, CP-77
059 inhibition of TNF; :, rolipram, inhibition of lethality; *,
rolipram, inhibition of TNF.
*
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Fig. 5. Effect of rolipram on carrageenan paw oedema. Fasted male
Lewis rates were injected in the footpad with 0-1 ml of a 1% solution of
carrageenan. Rolipram was given orally I h before carrageenan
injection (n 8). Paw diameter was measured with calipers 3 h after
carrageenan injection. *Significantly different (P < 005) from carra-
geenan control using Dunnett's multiple comparison.
mately 75% inhibition at the high dose (30mg/kg). There was
no detectable TNF-ct in the serum of rats injected in the paw
with TNF-cs, nor was there any TNF-a in normal paw
homogenates.
Adjuvant arthritis
Since PDE-IV inhibitors were successful in reducing serum
TNF-o levels and soft tissue swelling, these drugs were tested
in a chronic model of inflammation where TNF-a is also
thought to play a role in soft tissue swelling [16]. In the 3-
week adjuvant arthritic rat model, rats were dosed from day 1
with rolipram and CP-77 059 at 0 3, 1 and 3 mg/kg, po (Fig. 6).
Both drugs inhibited ankle swelling in a dose response fashion.
Rolipram was significantly inhibitory (32%) at 3 mg/kg, while
CP-77 059 significantly inhibited ankle swelling by 40% and
42% at 1 and 3 mg/kg, respectively.
Ankles were also evaluated radiologically using five indivi-
dually graded parameters (0-4). The features assessed were
bone demineralization, bone erosion, periostitis, cartilage space
reduction and soft tissue swelling as previously described [20].
As in inhibition of ankle swelling, rolipram and CP-77059
exhibited a significant and dose-dependent effect on each
individual parameter. Results depicting the total radiological
score show that rolipram at 3 mg/kg significantly reduced
radiological changes by 24%, while CP-77059 at all doses
significantly reduced radiological changes by 34-62% (Fig. 7).
In a second experiment, rolipram was dosed in a therapeutic
fashion, from day 7 to day 14. Under this regimen, rolipram
again exhibited inhibition of ankle swelling and radiological
damage of approximately 60% (data not shown).
DISCUSSION
Agents that elevate the concentration of intracellular cAMP
can inhibit inflammatory cell activities such as cytokine pro-
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Fig. 6. Inhibition of ankle swelling in adjuvant arthritic rats treated with
PDE-IV inhibitors. Male Lewis rats were injected subcutaneously in the
taIl with 0-05 ml Freund's complete adjuvant. Animals were dosed
orally from day to day 21 with rolipram or CP-77 059 (n= 8).
Measurement of ankle swelling was taken throughout the time course
using calipers. *Significantly different (P < 0-05) from arthritic control
using Dunnett's multiple comparison. A, Normal; A, arthritic; E,
rolipram (3 mg/kg); 0, rolipramn (1 mg/kg); VY, rolipramn (0-3 mg/kg);
EL1 CP-77 059 (3 mg/kg); 0, CP-77 059 (1 mg/kg); *, CP-77 059 (0-3
mg/kg).
duction, chemnotaxis, cytotoxicity and cell aggregation [1]. PDE
type-IV inhibitors, by virtue of their ability to block phospho-
diesterase activity in monocytic cells, thus elevating cAMP
levels, may be a class of compounds from which useful anti-
inflammatory drugs can be developed [ 1 -4].
This study demonstrated the effectiveness of PDE type-IV
inhibitors in various acute and chronic models of inflammation
in which TNF-a may have a pathological role. PDE-IV
inhibitors were potent suppressors of LPS-induced TNF-a
production in murine macrophages, whereas inhibitors selec-
tive for PDE-III or -V were much less active. Similar findings
have been reported for TNF-a, production in human mono-
cytes [5,7], supporting a major role for PDE-IV in the regula-
tion of both human and murine TNF-a production.
The in vivio potency of PDE-IV inhibitors was assessed in a
mouse model, where LPS was injected at a sublethal concen-
tration to induce appearance of serum TNF-a. The PDE-IV
inhibitors rolipram and CP-77 059 were orally active, dose-
dependent inhibitors of serum TNF-a levels in this system.
These PDE-IV inhibitors were tested in endotoxic shock
models, where serum TNF-a levels as well as mortality rate
could be measured. In the LPS/galactosamine model of endo-
toxic shock, rolipram and CP-77 059 not only effectively
reduced serum TNF-a levels, but also showed protective
effects in a dose-dependent fashion. However, reduction of
serum TNF-csi level did not guarantee complete protection
against lethality, since animals suffered 10000 mortality at
doses which inhibited serum TNF-a- levels over 8000. Since
shock is accompanied by a potentially lethal fall in blood
pressure, we considee the possibility that the hypotensive
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Fig. 7. Radiological score of adjuvant arthritic rats treated with PDE-
IV inhibitors. Total radiological score was based on five parameters
each scored from 0 (normal) to 4 (severe changes) as previously
described [15]. Thus a maximum total score could be 20. For further
details see Fig. 6 or Materials and Methods. *Significantly different
(P 0-05) from arthritic control using Dunnett's multiple comparison.
difference in the relatively high protective dose versus the much
lower TNF inhibitory dose. However, we have observed that
non-hypotensive compounds such as glucocorticoids also man-
ifested this discrepancy between the dose needed to protect
against lethal shock and the dose needed to inhibit serum TNF
levels. In addition, the PDE-IV inhibitors are active at high
doses, where the hypotensive side-effects are most pronounced.
If their haemodynamic profile contributed to their poor
potency in the LPS lethality assay, then one would have
predicted that the compounds would be active at the low
dose (where TNF inhibition was high and hypotensive effect
low) and inactive at the high dose (where the TNF inhibition
would be countered by the pronounced hypotensive effect).
While the haemnodynamnic effects of PDE-IV inhibitors may
cotrbute to this lack of correlation between survival rate and
reduction of serum TNF-a level, it is also possible that the
difference may be due to the greater relevance of localized
elevation of TNF-a in target tissues such as the lung, liver and
paw as opposed to systemic levels in the blood [16]. Alterna-
tively it may also be due in part to the pro-inflammatory
activity of cytokines not affected by PDE-IV inhibitors.
Since we have previously demonstrated that elevation of
TNF-a occurred in the paw but not in the serum of rats injected
with carrageenan [16], we tested rolipram for its anti-inflamn-
matory activity in this model of localized TNF-ce elevation.
Rolipram and CP-77 059 have previously been shown to
suppress carrageenan paw oedema [18]. We have confirmed
and extended that observation here by showing that rolipram
hibtedpaw infla mnmatio as local TNF-a
production. It cannot be ruled out that the anti-oedema action
of these agents may in part be the result of their induction of
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effect on neutrophils in vitro [21,22], it is likely that a substantial
component of the anti-inflammatory activity seen in the
carrageenan oedema model is due to inhibition of neutrophil
activity in vivo.
Encouraged by the activity ofthese prototypic PDE type-IV
inhibitors in models of acute inflammation, we next evaluated
the compounds in a chronic model of inflammation. The rat
adjuvant arthritis model mimics many aspects of human
rheumatoid arthritis, including elevated levels of TNF-a in
the arthritic joint [17,24]. In this model, rolipram and CP-
77059 not only reduced tissue oedema but also inhibited
radiological changes in the bone. In a previous paper we
compared ankle swelling and joint TNF-a levels in arthritic
rats treated with non-steroidal anti-inflammatory drugs or
immunosuppressive compounds [17]. It will also be important
to address the relationship between joint protection and joint
TNF-a levels in arthritic rats treated with PDE-IV inhibitors.
The most suitable candidates of PDE inhibitors for evalua-
tion in the clinic should possess the following properties: high
specificity to a selected PDE-IV isozyme, high potency, low
toxicity and good oral absorption. The recognition of multiple
isoforms [11,25] and a non-random tissue distribution of PDE-
IV [1-4,26] suggest the potential to develop more specific and
less toxic PDE-IV inhibitors. Synergism ofPDE inhibitors and
,82-agonists should be evaluated. In the sublethal LPS model of
serum TNF-a measurement, we have observed some mild
synergistic effect between salmeterol and rolipram (unpub-
lished data).
In conclusion, we have shown that PDE-IV inhibitors, in
addition to being potent suppressors ofTNF-a production, are
also good anti-inflammatory agents in several models of acute
and chronic inflammation. It is conceivable that the reported
activities of these compounds are due to unknown reactivities,
but the finding that compounds of two different chemical
structural classes have similar activities supports the notion
that PDE-IV inhibition is relevant. It should be emphasized
that while the suppressive effect on TNF-a production is one of
the most potent, consistent and complete inhibitory effects
known for PDE inhibitors in relation to inflammatory cell
function, the extent to which this contributes to anti-inflam-
matory activity in each of these models will not be clear until
the role of TNF-a in vivo is better defined. For example, PDE-
IV inhibition has been shown to have suppressive effects on
several other potentially pro-inflammatory cellular activities,
including IL-1,3 [7] and LTB4 [27] production by monocytes,
neutrophil respiratory burst [28], histamine and LTB4 release
from basophils [29], histamine and LTC4 from mast cells [27]
and T lymphocyte blastogenesis [30]. In addition, there are
several examples of cAMP-regulated inflammatory cell func-
tion which have not been fully explored with respect to PDE
inhibition. Nevertheless, these data suggest that a specific PDE-
IV inhibitor has potential therapeutic utility for acute and
chronic inflammatory disease, and are consistent with the
hypothesis that TNF-ca is an important mediator in inflamma-
tory disease.
ACKNOWLEDGMENTS
We would like to thank Richard Silverstein and Tammy Stone for their
technical assistance. We also thank Drs Paul Feldman, lain D. Dukes
and Alan D. Proia for critical review of the manuscript.
REFERENCES
1 Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new oppor-
tunities for the treatment of asthma. Chest 1991; 46:512-23.
2 Giembycz MA, Dent G. Prospects for selective cyclic nucleotide
phosphodiesterase inhibitors in the treatment of bronchial asthma.
Clin Exp Allergy 1992; 22:337-44.
3 Torphy TJ, Livi GP, Christensen SB. Novel phosphodiesterase
inhibitors for the therapy of asthma. Drug News and Perspectives
1993; 6:203-14.
4 Lowe III JA, Cheng JB. The PDE IV family ofcalcium-independent
phosphodiesterase enzymes. Drugs of the Future 1992; 17:799-807.
5 Cohan VL, Naclerio BA. LPS-induced tumor necrosis factor alpha
(TNFa) release by isolated human monocytes is sensitive to agents
that elevate intracellular levels of cyclic AMP. J Immunol 1993; 150
(No 8,Pt 2):212A.
6 Sever A, Rapson NT, Hunter C A, Liew FY. Regulation of tumor
necrosis factor production by adrenaline and ,3-adrenergic agonists.
J Immunol 1992; 148:3441-5.
7 Molnar-Kimber KL, Yonno L, Heaslip RJ et al. Differential
regulation of TNF-a and IL-1,3 production from endotoxin stimu-
lated human mocytes by phosphodiesterase inhibitors. Mediator
Infl 1992; 1:411-7.
8 Semmler J, Wachtel H, Endres S. The specific type IV phospho-
diesterase inhibitor rolipram suppresses tumor necrosis factor-
production by human mononuclear cells. Int J Immunopharmacol
1993; 15:409-13.
9 Renz H, Gong JH, Schmidt A et al. Release oftumor necrosis factor
from macrophages: enhancement and suppression are dose depen-
dently regulated by prostaglandin E2 and cyclic nucleotides. J
Immunol 1988; 144:2388-93.
10 Sekut L, Champion BR, Page K, Menius JA, Connolly K. Anti-
inflammatory activity of salmeterol: down regulation of cytokine
production. Clin Exp Immunol 1995; 99:461-6.
11 Livi GP, Kmetz P, McHale MM etal. Cloning and expression of
cDNA for a human low-Ki, rolipram-sensitive cyclic AMP phos-
phodiesterase. Mol Cell Biol 1990; 10:2678-786.
12 Jaittela M. Biology of disease; biologic activites and mechanisms of
action of tumor necrosis factor-a/cachectin. Lab Invest 1991;
64:724-42.
13 Piquet PF, Grau GE, Vassalli P. Tumor necrosis factor and
imunopathology. Immunol Res 1991; 10: 122-40.
14 Fiers W. Tumor necrosis factor; characterization at the molecular,
cellular and in vivo level. FEBS 1991; 285:199-212.
15 Pfeffer K, Matsuyama T, Kunding TM et al. Mice deficient for the
55 kD tumor necrosis factor receptor are resistant to endotoxic
shock, yet succumb to L. monocytogenes infection. Cell (USA) 1993;
73:457-67.
16 Sekut L, Menius JA Jr, Brackeen MF et al. Evaluation of the
significance of elevated levels of systemic and localized TNF in
different animal models of inflammation. J Lab Clin Med 1994;
124:813-20.
17 Smith-Oliver T, Noel LS, Stimpson SA et al. Elevated levels ofTNF
in the joints of adjuvant arthritic rats. Cytokine 1993; 5:298-305.
18 Lowe JA, Archer RL, Chapin DS et al. Structure-activity relation-
ship of quinazolinedione inhibitors of calcium-independent pho-
phodiesterase. J Med Chem 1991; 34:624-8.
19 Connolly KM, Stecher VJ, Kent L. Examination of interleukin-l
activity, the acute phase response, and leukocyte subpopulactions in
rats with adjuvant-induced arthritis. J Lab Clin Med 1988; 111:341-
7.
20 Clark RL, Cuttino JT, Anderle SK etal. Radiologic analysis of
arthritis in rats after systemic injection of streptococcal cell walls.
Arthritis Rheum 1979; 22:25-35.
21 Verghese MW, Brown TA, Irsula 0 et al. Anti-neutrophil activity of
cyclic nucleotides with varying cardiotonic potencies. J Mol Cell
Cardiol 1989; 21:S61.
132 L. Sekut et al.
22 Nielson CP, Vestal RE, Sturm RJ et al. Effects of selective phos-
phodiesterase inhibitors on the polymorphonuclear leukocyte
respiratory burst. J Allergy Clin Immunol 1990; 86: 801-8.
23 Peachell PT, Undem BJ, Schleimer RP et al. Preliminary identifica-
tion and role of phosphodiesterase isoenzymes in human basophils.
Immunology 1992; 148:2503-10.
24 Lewis AJ, Carlson RP, Chang J. Experimental models of inflam-
mation. In: Bonta IL, Brag MA, Parnham MJ, eds. The pharma-
cology of inflammation. New York: Elsevier 1985: 371-97.
25 McLaughlin MM, Cieslinski LB, Burman M etal. A low Kin,
rolipram-sensitive, cAMP-specific phosphodiesterase from human
brain. J Biol Chem 1993; 268:6470-6.
26 Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide
phosphodiesterase isozymes and the design of selective inhibitors.
Trends Pharm Sci 1990; 11:150-5.
27 Griswold DE, Webb EF, Breton J etal. Effect of selective
phosphodiesterase type IV inhibitor, rolipram, on fluid and
cellular phases of inflammatory response. Inflammation 1993;
17:333-44.
28 Neilson CP, Vestal RE, Sturm RJ et al. Effects of selective phopho-
diesterase inhibitors on the polymorphonuclear leukocyte respira-
tory burst. J Allergy Clin Immunol 1990; 86:801-8.
29 Peachell PT, Undem BJ, Schleimer RP et al. Preliminary identifica-
tion and role of phosphodiesterase isozymes in human basophils. J
Immunol 1992; 148:2503-10.
30 Robicsek SA, Blanchard DK, Djeu JY et al. Multiple high-affinity
cAMP-phosphodiesterases in human T-lymphocytes. Biochem
Pharmacol 1991; 42:869-77.
